Coherus Biosciences Inc (NASDAQ:CHRS)’s traded shares stood at 2.09 million during the last session, with the company’s beta value hitting 0.54. At the close of trading, the stock’s price was $2.39, to imply a decrease of -1.24% or -$0.03 in intraday trading. The CHRS share’s 52-week high remains $8.65, putting it -261.92% down since that peak but still an impressive 40.17% since price per share fell to its 52-week low of $1.43. The company has a valuation of $266.15M, with an average of 3.02 million shares in intraday trading volume over the past 10 days and average of 4.91 million shares over the past 3 months.
Coherus Biosciences Inc (NASDAQ:CHRS) trade information
After registering a -1.24% downside in the last session, Coherus Biosciences Inc (CHRS) has traded red over the past five days. The stock hit a weekly high of 2.51, dropping -1.24% in its intraday price action. The 5-day price performance for the stock is -4.78%, and 1.27% over 30 days. With these gigs, the year-to-date price performance is -28.23%. Short interest in Coherus Biosciences Inc (NASDAQ:CHRS) saw shorts transact 25.91 million shares and set a 9.28 days time to cover.
Coherus Biosciences Inc (CHRS) estimates and forecasts
Looking at statistics comparing Coherus Biosciences Inc share performance against respective industry, we note that the company has outperformed competitors. Coherus Biosciences Inc (CHRS) shares are -39.80% down over the last 6 months, with its year-to-date growth rate higher than industry average at 100.51% against 13.00%. Revenue is forecast to grow 69.30% this quarter before jumping 42.10% for the next one. The rating firms project that company’s revenue will grow 1.80% compared to the previous financial year.
Revenue forecast for the current quarter as set by 5 analysts is $81.7 million. Meanwhile, for the quarter ending Jun 2024, a total of 5 analyst(s) estimate revenue growth to $53.68 million.
CHRS Dividends
Coherus Biosciences Inc has its next earnings report out between May 06 and May 10. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too. Coherus Biosciences Inc has a forward dividend ratio of 0, with the share yield ticking at 0.00% to continue the rising pattern observed over the past year. The company’s average dividend yield trailing the past 5-year period is 0.00%.
Coherus Biosciences Inc (NASDAQ:CHRS)’s Major holders
Coherus Biosciences Inc insiders hold 1.35% of total outstanding shares, with institutional holders owning 78.04% of the shares at 79.12% float percentage. In total, 78.04% institutions holds shares in the company, led by Blackrock Inc.. As of Jun 29, 2023, the company held over 15.79 million shares (or 16.71% of shares), all amounting to roughly $67.41 million.
The next major institution holding the largest number of shares is Vanguard Group Inc with 8.85 million shares, or about 9.37% of shares outstanding. As of the market price on Jun 29, 2023, these shares were worth $37.79 million.
We also have Vanguard Total Stock Market Index Fund and JP Morgan Small Cap Growth Fund as the top two Mutual Funds with the largest holdings of the Coherus Biosciences Inc (CHRS) shares. Going by data provided on Jun 29, 2023, Vanguard Total Stock Market Index Fund holds roughly 2.73 million shares. This is just over 2.89% of the total shares, with a market valuation of $11.66 million. Data from the same date shows that the other fund manager holds a little less at 2.44 million, or 2.58% of the shares, all valued at about 10.41 million.
